The Evolving Role of Immune Checkpoint Inhibitors in Cancer Treatment.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  The Oncologist

• Publication date

  2015-07-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1634/theoncologist.2014-0422PMID 26069281PMCID PMC4492230
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma.

  2015cited by this paper
• Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma.

  2015cited by this paper
• Nivolumab in previously untreated melanoma without BRAF mutation.

  2015cited by this paper
• Five-year survival rates for treatment-naive patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial.

  2015cited by this paper
• Nivolumab (anti-PD-1; BMS-936558, ONO-4538) and ipilimumab in first-line NSCLC: Interim phase I results.

  2014cited by this paper
• Preliminary Results of a Phase I Study of Nivolumab (BMS-936558) in Patients with Relapsed or Refractory Lymphoid Malignancies

  2014cited by this paper
• Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with platinum-based doublet chemotherapy (PT-DC) in advanced non-small cell lung cancer (NSCLC).

  2014cited by this paper
• Efficacy and safety of the anti-PD-1 monoclonal antibody MK-3475 in 411 patients (pts) with melanoma (MEL).

  2014cited by this paper
• Phase 2, multicenter, safety and efficacy study of pidilizumab in patients with metastatic melanoma.

  2014cited by this paper
• Mutational heterogeneity in cancer and the search for new cancer genes

  2014cited by this paper
• Safety and clinical activity of MK-3475 in previously treated patients (pts) with non-small cell lung cancer (NSCLC).

  2014cited by this paper
• MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

  2014cited by this paper
• A phase 1 study of PF-05082566 (anti-4-1BB) in patients with advanced cancer.

  2014cited by this paper
• Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

  2014cited by this paper
• Evaluation of immune-related response criteria (irRC) in patients (pts) with advanced melanoma (MEL) treated with the anti-PD-1 monoclonal antibody MK-3475.

  2014cited by this paper
• Safety and response with nivolumab (anti-PD-1; BMS-936558, ONO-4538) plus erlotinib in patients (pts) with epidermal growth factor receptor mutant (EGFR MT) advanced NSCLC.

  2014cited by this paper
• Long-term survival of ipilimumab-naive patients (pts) with advanced melanoma (MEL) treated with nivolumab (anti-PD-1, BMS-936558, ONO-4538) in a phase I trial.

  2014cited by this paper
• Clinical efficacy and correlation with tumor PD-L1 expression in patients (pts) with melanoma (MEL) treated with the anti-PD-1 monoclonal antibody MK-3475.

  2014cited by this paper
• Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial.

  2014cited by this paper
• Safety and Clinical Activity of MK-3475 as Initial Therapy in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

  2014cited by this paper
• Nivolumab (anti-PD-1, BMS-936558, ONO-4538) in patients (pts) with advanced non-small-cell lung cancer (NSCLC): Survival and clinical activity by subgroup analysis.

  2014cited by this paper
• Sequential Treatment with Ipilimumab and BRAF Inhibitors in Patients With Metastatic Melanoma: Data From the Italian Cohort of the Ipilimumab Expanded Access Program

  2014cited by this paper
• Molecular Pathways Molecular Pathways : Resistance to Kinase Inhibitors and Implications for Therapeutic Strategies

  2014cited by this paper
• Ipilimumab versus placebo after complete resection of stage III melanoma: Initial efficacy and safety results from the EORTC 18071 phase III trial.

  2014cited by this paper
• Combinations of radiation therapy and immunotherapy for melanoma: a review of clinical outcomes.

  2014cited by this paper
• Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS-936558, ONO-4538) and ipilimumab (IPI) concurrent therapy in advanced melanoma (MEL).

  2014cited by this paper
• Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti–PD-1 Therapy

  2014cited by this paper
• A phase Ib study of MK-3475 in patients with human papillomavirus (HPV)-associated and non-HPV–associated head and neck (H/N) cancer.

  2014cited by this paper
• OX40 is a potent immune-stimulating target in late-stage cancer patients.

  2013cited by this paper
• Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies.

  2013cited by this paper
• Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma.

  2013cited by this paper
• Combining radiotherapy and cancer immunotherapy: a paradigm shift.

  2013cited by this paper
• Enhancing immunotherapy using chemotherapy and radiation to modify the tumor microenvironment

  2013cited by this paper
• Tumor-specific cytotoxic T cells are crucial for efficacy of immunomodulatory antibodies in patients with lung cancer.

  2013cited by this paper
• Efficacy and safety of ipilimumab in metastatic melanoma patients surviving more than 2 years following treatment in a phase III trial (MDX010-20).

  2013cited by this paper
• Ipilimumab and its toxicities: a multidisciplinary approach.

  2013cited by this paper
• Cancer immunotherapy strategies based on overcoming barriers within the tumor microenvironment.

  2013cited by this paper
• Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial.

  2013cited by this paper
• Interleukin 2 in cancer therapy.

  2013cited by this paper
• Exploring novel immune-related toxicities and endpoints with immune-checkpoint inhibitors in non-small cell lung cancer.

  2013cited by this paper
• Severe Cutaneous and Neurologic Toxicity in Melanoma Patients during Vemurafenib Administration Following Anti-PD-1 Therapy

  2013cited by this paper
• Immunogenic cell death in cancer therapy.

  2013cited by this paper
• Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic melanoma (mM).

  2013cited by this paper
• Nivolumab (anti-PD-1; BMS-936558; ONO-4538) in patients with advanced solid tumors: Survival and long-term safety in a phase I trial.

  2013cited by this paper
• Hepatotoxicity with combination of vemurafenib and ipilimumab.

  2013cited by this paper
• Nivolumab plus ipilimumab in advanced melanoma.

  2013cited by this paper
• Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma.

  2013cited by this paper
• Mutational heterogeneity in cancer and the search for new cancer genes

  2013cited by this paper
• High-dose interleukin-2: is it still indicated for melanoma and RCC in an era of targeted therapies?

  2013cited by this paper
• The blockade of immune checkpoints in cancer immunotherapy

  2012cited by this paper
• Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

  2012cited by this paper
• Immunotherapy of cancer in 2012

  2012cited by this paper
• Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study.

  2012cited by this paper
• Targeting immune checkpoints: releasing the restraints on anti-tumor immunity for patients with melanoma.

  2012cited by this paper
• Patient Responses to Ipilimumab, a Novel Immunopotentiator for Metastatic Melanoma: How Different are these From Conventional Treatment Responses?

  2012cited by this paper
• Cancer immunotherapy

  2012cited by this paper
• Molecular Pathways: Next-Generation Immunotherapy—Inhibiting Programmed Death-Ligand 1 and Programmed Death-1

  2012cited by this paper
• Analysis of Spontaneous Tumor-Specific CD4 T-cell Immunity in Lung Cancer Using Promiscuous HLA-DR Telomerase-Derived Epitopes: Potential Synergistic Effect with Chemotherapy Response

  2012cited by this paper
• Raising the Bar: The Curative Potential of Human Cancer Immunotherapy

  2012cited by this paper
• Immunotherapy of Cancer with 4-1BB

  2012cited by this paper
• Combining immunotherapy and targeted therapies in cancer treatment

  2012cited by this paper
• Cellular constituents of immune escape within the tumor microenvironment.

  2012cited by this paper
• Ipilimumab in Combination With Paclitaxel and Carboplatin As First-Line Treatment in Stage IIIB/IV Non–Small-Cell Lung Cancer: Results From a Randomized, Double-Blind, Multicenter Phase II Study

  2012cited by this paper
• Evolution of end points for cancer immunotherapy trials.

  2012cited by this paper
• Immuno-oncology: understanding the function and dysfunction of the immune system in cancer.

  2012cited by this paper
• Combination immunotherapy approaches.

  2012cited by this paper
• Sequencing of BRAF inhibitors and ipilimumab in patients with metastatic melanoma: a possible algorithm for clinical use

  2012cited by this paper
• Cancer immunotherapy comes of age.

  2011cited by this paper
• Autoimmunity associated with immunotherapy of cancer.

  2011cited by this paper
• IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect.

  2011cited by this paper
• Cancer immunotherapy comes of age

  2011cited by this paper
• Natural innate and adaptive immunity to cancer.

  2011cited by this paper
• Blockade of the B7-H1/PD-1 Pathway for Cancer Immunotherapy

  2011cited by this paper
• CD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and Humans

  2011cited by this paper
• Ipilimumab plus dacarbazine for previously untreated metastatic melanoma.

  2011cited by this paper
• Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy

  2011cited by this paper
• Tumor immunosurveillance in human cancers

  2011cited by this paper
• PROVENGE (Sipuleucel-T) in Prostate Cancer: The First FDA-Approved Therapeutic Cancer Vaccine

  2011cited by this paper
• Combination strategies for enhancing the efficacy of immunotherapy in cancer patients

  2010cited by this paper
• Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity.

  2010cited by this paper
• Sipuleucel-T immunotherapy for castration-resistant prostate cancer.

  2010cited by this paper
• 自然杀伤细胞与癌症——杀伤细胞免疫球蛋白样受体（KIR）的调控

  2010cited by this paper
• The emerging toxicity profiles of anti-CTLA-4 antibodies across clinical indications.

  2010cited by this paper
• Vaccines against Human Carcinomas: Strategies to Improve Antitumor Immune Responses

  2010cited by this paper
• First-line chemoimmunotherapy in metastatic breast carcinoma: combination of paclitaxel and IMP321 (LAG-3Ig) enhances immune responses and antitumor activity

  2010cited by this paper
• Improved survival with ipilimumab in patients with metastatic melanoma.

  2010cited by this paper
• Natural killer cells and cancer: Regulation by the killer cell Ig-like receptors (KIR)

  2009cited by this paper
• Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells.

  2009cited by this paper
• Regulatory T cells: how do they suppress immune responses?

  2009cited by this paper
• Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria

  2009cited by this paper
• A Phase I Pharmacokinetic and Biological Correlative Study of IMP321, a Novel MHC Class II Agonist, in Patients with Advanced Renal Cell Carcinoma

  2009cited by this paper
• Cancer chemotherapy: not only a direct cytotoxic effect, but also an adjuvant for antitumor immunity

  2008cited by this paper
• The Role of Death Receptor Ligands in Shaping Tumor Microenvironment

  2007cited by this paper
• Immunostimulatory monoclonal antibodies for cancer therapy

  2007cited by this paper
• Mechanisms of immune evasion by tumors.

  2006cited by this paper
• Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206.

  2005cited by this paper
• Immunotherapy: past, present and future

  2003cited by this paper
• Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase

  2003cited by this paper
• Cancer immunoediting: from immunosurveillance to tumor escape

  2002cited by this paper
• Interleukin-2 in Cancer Therapy

  2000cited by this paper

• Phase 1b/2 study of ADG106, a 4-1BB/CD137 agonist, in combination with toripalimab in patients with advanced solid tumors

  2025cites this paper
• hsa-miR-145-3p defines a fibro-inflammatory bladder cancer subtype with distinct therapeutic vulnerabilities

  2025cites this paper
• The Development and Assessment of a Unique Disulfidptosis-Associated lncRNA Profile for Immune Microenvironment Prediction and Personalized Therapy in Gastric Adenocarcinoma

  2025cites this paper
• Simulated Rheumatoid Arthritis Induced by Immune Checkpoint Inhibitor

  2025cites this paper
• Type 2 Immunity Links Eczematous and Lichenoid Eruptions Caused by Immune Checkpoint Inhibitors.

  2025cites this paper
• Immune-mediated gastritis in a patient with breast cancer due to therapy with immune checkpoint inhibitor pembrolizumab: a case report

  2025cites this paper
• Re-challenge with immune checkpoint inhibitors as second-line treatment in advanced esophageal squamous cell carcinoma: a real-world multicenter retrospective study.

  2025cites this paper
• Nutrition in Oncology: Overcoming Challenges to Optimize the Patient Journey from Prehabilitation to Rehabilitation

  2025cites this paper
• Advances in TIL therapy: Expanding the horizons beyond melanoma.

  2025cites this paper
• Comprehensive Pan-Cancer Analysis and Functional Studies Reveal SLC2A6 as a Ferroptosis Modulator in Hepatocellular carcinoma

  2025cites this paper
• Bioinformatics and imaging omics: Lung cancer prognosis and immunity impact

  2025cites this paper
• Bacterial Sialidases: Biological Significance and Application

  2025cites this paper
• FOLFOX-HAIC combined with targeted immunotherapy for initially unresectable hepatocellular carcinoma: a real-world study

  2024cites this paper
• Sensory nerve release of CGRP increases tumor growth in HNSCC by suppressing TILs.

  2024cites this paper
• CRISPRing KRAS: A Winding Road with a Bright Future in Basic and Translational Cancer Research

  2024cites this paper
• The Biochemistry of Immune Checkpoint Inhibitors and The Role of Nursing in Cancer Care.

  2024cites this paper
• Immune checkpoint inhibitors and neurotoxicity: a focus on diagnosis and management for a multidisciplinary approach

  2024cites this paper
• The Development of Persistent Gastrointestinal Symptoms in Patients With Melanoma Who Have Had an Immune Checkpoint Inhibitor-Related Gastrointestinal Toxicity

  2024cites this paper
• The advancement in the application of immune checkpoint inhibitors in pNET

  2024cites this paper
• Future applications of host direct therapies for infectious disease treatment

  2024cites this paper
• Landscape of targeted therapies for lung squamous cell carcinoma

  2024cites this paper
• Reporting Quality in Health Economic Evaluation Studies of Immune Checkpoint Inhibitors: A Systematic Review

  2024cites this paper
• Endoplasmic reticulum-targeted iridium(III) photosensitizer induces pyroptosis for augmented tumor immunotherapy.

  2024cites this paper
• Anti-PD-L1 antibody retains antitumour effects while mitigating immunotherapy-related colitis in bladder cancer-bearing mice after CT-mediated intratumoral delivery.

  2024cites this paper
• Advances of ultrasound in tumor immunotherapy.

  2024cites this paper
• Comparison of programmed death‐ligand 1 expression in adenocarcinoma and squamous cell carcinoma of the cervix in paraffin blocks of patients with cervical cancer

  2024cites this paper
• First-in-Human Stage III/IV Melanoma Clinical Trial of Immune Priming Agent IFx-Hu2.0

  2024cites this paper
• Cutaneous adverse events due to checkpoint inhibitors – a retrospective analysis at a tertiary referral hospital in Switzerland 2019-2022

  2024cites this paper
• A Prognosis and Immunological Study of Cellular Aging Related lncRNAs in Lung Adenocarcinoma

  2024cites this paper
• β-Glucan-conjugated anti-PD-L1 antibody enhances antitumor efficacy in preclinical mouse models.

  2024cites this paper
• Targeting Dual Immune Checkpoints PD‐L1 and HLA‐G by Trispecific T Cell Engager for Treating Heterogeneous Lung Cancer

  2024cites this paper
• Unlocking the potential of immunotherapy in platinum-resistant ovarian cancer: rationale, challenges, and novel strategies

  2024cites this paper
• Targeting Gsk3a reverses immune evasion to enhance immunotherapy in hepatocellular carcinoma

  2024cites this paper
• Impact of CRISPR/Cas9-Mediated CD73 Knockout in Pancreatic Cancer

  2023cites this paper
• Immunotherapy for Metastatic Non-Small Cell Lung Cancer: Therapeutic Advances and Biomarkers

  2023cites this paper
• Comprehensive overview of biomarkers to predict response to immune checkpoint therapy in lung cancer

  2023cites this paper
• The Interaction of Programmed Cell Death Protein and Its Ligands with Non-Coding RNAs in Neoplasms: Emerging Anticancer Immunotherapeutics

  2023cites this paper
• Case Report: sintilimab-induced Stevens-Johnson Syndrome in a patient with advanced lung adenocarcinoma

  2023cites this paper
• Clinical Observation of Immunotherapy Combined with Antiangiogenic Targeted Drugs in the Treatment of 20 Cases Advanced Hepatocellular Carcinoma

  2023cites this paper
• Radiation and Immune Checkpoint Inhibitors: Combination Therapy for Treatment of Hepatocellular Carcinoma

  2023cites this paper
• Gut microbiome on immune checkpoint inhibitor therapy and consequent immune-related colitis: a review

  2023cites this paper
• Pan-cancer analysis reveals potential of FAM110A as a prognostic and immunological biomarker in human cancer

  2023cites this paper
• Current Status in Rechallenge of Immunotherapy

  2023cites this paper
• Microsatellite Instability and Immune Response: From Microenvironment Features to Therapeutic Actionability—Lessons from Colorectal Cancer

  2023cites this paper
• The current state of knowledge on small cell and non-small cell lung cancer and the position of durvalumab immunotherapy in lung cancer treatment. A review.

  2023cites this paper
• Efficacy and safety of immune checkpoint inhibitors for patients with prostate cancer: a systematic review and meta-analysis

  2023cites this paper
• Cutaneous Side Effects of Modern Targeted Therapy and Immunotherapy in Patients with Dermatological Malignancies

  2023cites this paper
• Checkpoint inhibitor hepatotoxicity: pathogenesis and management.

  2023cites this paper
• Clinical Observation of 15 Cases of Locally Advanced Lung Squamous Cell Carcinoma Treated with Immunotherapy Combined with Radiotherapy

  2023cites this paper
• Crosstalk of Mast Cells and Natural Killer Cells with Neurons in Chemotherapy-Induced Peripheral Neuropathy

  2023cites this paper
• Immune Checkpoint Inhibitors Therapy as the Game-Changing Approach for Pediatric Lymphoma: A Brief Landscape.

  2023cites this paper
• Drug-Induced Liver Injury due to Biologics and Immune Check Point Inhibitors.

  2023cites this paper
• Exploring long-term responses to immune checkpoint inhibitors in recurrent and metastatic head and neck squamous cell carcinoma.

  2023cites this paper
• Immune checkpoint inhibitors and cancer immunotherapy by aptamers: an overview

  2023cites this paper
• Immune Checkpoint Inhibitor-induced Pancreatitis with Pancreatic Enlargement Mimicking Autoimmune Pancreatitis: A Case Report and Review of the Literature

  2023cites this paper
• Proinflammatory allogeneic dendritic cells enhance the therapeutic efficacy of systemic anti-4-1BB treatment

  2023cites this paper
• IP-score correlated to endogenous tumour antigen peptide processing: A candidate clinical response score algorithm of immune checkpoint inhibitors therapy in multiple cohorts

  2023cites this paper
• Drug induced liver injury by immunotherapy.

  2022cites this paper
• Isolated adrenocorticotropic hormone deficiency associated with sintilimab therapy in a patient with advanced lung adenocarcinoma: a case report and literature review

  2022cites this paper
• Biological Evaluation and Reverse Pharmacophore Mapping of Innovative Bis-Triazoles as Promising Anticancer Agents

  2022cites this paper
• Immune Checkpoint Inhibitors: Recent clinical advances and future prospects.

  2022cites this paper
• Prognostic and Predictive Role of Tumor-Infiltrating Lymphocytes (TILs) in Ovarian Cancer

  2022cites this paper
• Efficacy and safety of immune checkpoint inhibitors-combined antiangiogenic drugs in the treatment of hepatocellular carcinoma: A systematic review and meta analysis

  2022cites this paper
• Checkpoint inhibitor-induced hepatotoxicity: Role of liver biopsy and management approach

  2022cites this paper
• Role of cytoreductive surgery in the era of immunotherapy

  2022cites this paper
• Case Report of a Malignant Melanoma Patient with Longitudinally Extensive Transverse Myelitis: Immune-Related Adverse Event or Human Herpesvirus-7 Infection?

  2022cites this paper
• IMMUNOTHERAPY Mogamulizumab in Combination with Nivolumab in a Phase I/II Study of Patients with Locally Advanced or Metastatic Solid Tumors

  2022cites this paper
• Anti-CSF-1R emactuzumab in combination with anti-PD-L1 atezolizumab in advanced solid tumor patients naïve or experienced for immune checkpoint blockade

  2022cites this paper
• Multilevel mechanism of immune checkpoint inhibitor action in solid tumors: History, present issues and future development

  2022cites this paper
• Oxidative Stress in Cancer Immunotherapy: Molecular Mechanisms and Potential Applications

  2022cites this paper
• Immune-Related Adverse Events (irAEs) in Cancer, with Inputs from a Nursing Expert: A Review

  2022cites this paper
• Efficiency of Electronic Health Record Assessment of Patient-Reported Outcomes After Cancer Immunotherapy

  2022cites this paper
• Topoisomerase I inhibitors: Challenges, progress and the road ahead.

  2022cites this paper
• Pembrolizumab in advanced renal cell carcinoma: a meta-analysis providing level 1a evidence.

  2022cites this paper
• Lymphocyte dynamics during and after chemo-radiation correlate to dose and outcome in stage III NSCLC patients undergoing maintenance immunotherapy.

  2022cites this paper
• Tanshinone IIA: New Perspective on the Anti-Tumor Mechanism of A Traditional Natural Medicine.

  2022cites this paper
• Immunopharmacogenomics: a hope in the treatment of carcinoma

  2022cites this paper
• Isolated adrenocorticotropic hormone deficiency and sialadenitis associated with nivolumab: a case report

  2022cites this paper
• Mechanisms of Resistance and Strategies to Combat Resistance in PD-(L)1 Blockade

  2022cites this paper
• ARRY-382 in Combination with Pembrolizumab in Patients with Advanced Solid Tumors: Results from a Phase 1b/2 Study

  2022cites this paper
• A novel risk model based on cuproptosis-related lncRNAs predicted prognosis and indicated immune microenvironment landscape of patients with cutaneous melanoma

  2022cites this paper
• Highlights on Ocular Toxicity of Immune Checkpoint Inhibitors at a US Tertiary Cancer Center

  2022cites this paper
• Elective nodal irradiation mitigates local and systemic immunity generated by combination radiation and immunotherapy in head and neck tumors

  2022cites this paper
• Mogamulizumab in Combination with Nivolumab in a Phase I/II Study of Patients with Locally Advanced or Metastatic Solid Tumors

  2021cites this paper
• Mechanisms of Immune Checkpoint Inhibitor-Mediated Colitis

  2021cites this paper
• Medical Therapy for Craniopharyngiomas.

  2021cites this paper
• Cancers

  2021cites this paper
• Targeting MDSC for Immune-Checkpoint Blockade in Cancer Immunotherapy: Current Progress and New Prospects

  2021cites this paper
• Immune checkpoint inhibitors: An emergency medicine focused review.

  2021cites this paper
• Hepatocellular Carcinoma Immunotherapy.

  2021cites this paper
• Follow-up Care for Patients Receiving Immune Checkpoint Inhibitors

  2021cites this paper
• Immunotherapy of cancer

  2021cites this paper
• Exosomes derived from immunogenically dying tumor cells as a versatile tool for vaccination against pancreatic cancer.

  2021cites this paper
• Role of Bioinformatics in cancer research and drug development

  2021cites this paper
• Current status of cancer immunotherapy with immune checkpoint inhibitors

  2021cites this paper
• The Impact of Long-Term Antibiotic Therapy of Cutaneous Adverse Reactions to EGFR Inhibitors in Colorectal Cancer Patients

  2021cites this paper
• T‐Cell‐Derived Nanovesicles for Cancer Immunotherapy

  2021cites this paper
• Preclinical Characterization of a Novel Anti-Cancer PD-L1 Inhibitor RPH-120

  2021cites this paper
• CD137 and PD-L1 targeting with immunovirotherapy induces a potent and durable antitumor immune response in glioblastoma models

  2021cites this paper
• Immune Regulatory Processes of the Tumor Microenvironment under Malignant Conditions

  2021cites this paper